Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2024 07:00 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Reports Third Quarter 2024 Financial Results

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...